Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

Cuba reports 92.4 percent efficacy for 3 dose SOBERANA 02 COVID-19 vaccine

Cuba reports 92.4 percent efficacy for 3 dose SOBERANA 02 COVID-19 vaccine

A new study describes the results of the safety and efficacy phase trials of a new COVID-19 vaccine from Cuba.

Study findings
Vaccines are a high-priority public health intervention; however, the success of the vaccination program depends on the speed and coverage of the rollout.

SOBERANA 02 is the first conjugated vaccine to be developed against SARS-CoV-2. The vaccine uses the recombinant receptor-binding domain (RBD) of the viral spike protein, chemically attached to the tetanus toxoid antigen in a molar ratio of 6:1 and adsorbed on 500 micrograms (µg) of alumina. Conversely, SOBERANA Plus contains dimeric RBD 50 µg, adsorbed on 1,250 µg alumina, having been developed as a “universal booster.”

With this, SOBERANA 02 joins other conjugated vaccines, such as the protein-polysaccharide conjugated vaccine against Hemophilus influenzae type b, Neisseria meningitidis, and Streptococcus pneumoniae.

With the current experimental vaccine, two doses have been found to elicit neutralizing antibodies, along with both memory B- and T-cells, secreting interferon-gamma (IFN-γ) as well as showing a T-helper cell type 1 (Th1) profile of immunity.

This vaccine could also be used as a heterologous third booster dose to enhance the level of neutralizing anti-RBD antibodies. Following successful Phase 1 and 2a trials, the Phase 3 trial was launched to assess the efficacy and safety profile of two usage patterns of SOBERANA, which include a two-dose regimen of SOBERANA 02, and evaluate this regimen when combined with the third dose of SOBERANA Plus.

The participants of the current study were all healthy adults from different parts of Havana, Cuba. Each participant was assigned in a randomized double-blinded placebo-controlled manner to vaccine and control groups. The mean age was 48 years, with an almost equal number of males and females.

One group (A) received the two-dose homologous regimen, the second (group B) the heterologous three-dose regimen, and the third (group C) the placebo. None of the final participants had confirmed SARS-CoV-2 infection at any point.

There were 0.8 COVID-19 cases per 1,000 person-years (PY) in group A, and 2.7 in the placebo, corresponding to 198 and 155 cases, respectively, indicating a two-dose vaccine efficacy (VE) of 71% compared to placebo.

With the heterologous three-dose regimen, the VE was greater than 92% relative to the placebo, at an incidence of 0.1 per 1,000 PY in group B (170 vs 155 cases in groups B and C, respectively).

Protection against severe COVID-19 was 63% in group A and 100% for group B. Comparatively, when considering deaths due to COVID-19, VE was 59% and 100%, respectively.

Implications
The current study shows the SOBERANA 02 conjugate vaccine to be safe and effective in preventing severe COVID-19 in adults up to 80 years of age. A VE of over 60% was expected during the period when the ancestral SARS-CoV-2 strain was circulating. However, a VE of 62% was achieved, even during a period when the dominant strain was the Beta SARS-CoV-2 variant of concern (VOC).

The SARS-CoV-2 Beta strain made up 74% of isolated sequences at the time in Havana. The high VE was observed in spite of the presence of the E484K mutation that confers resistance to neutralizing antibodies in the sera of individuals who have been immunized by natural infection or by vaccination.

By the time the final analysis was conducted, the Delta VOC was the dominant circulating strain; however, the VE at two doses was 71% at this time. The heterologous three-dose regimen led to VE exceeding 92%, but it still remained high irrespective of VOCs in circulation.

Even at the two-month mark, the safety profile was impressive, with mild transient local reactions and no serious adverse reactions reported. The third dose of the vaccine had few side effects.

The final VE comes from the figures compiled 14 days after the last immunization, or 70 days after the first dose with the triple-dose regimen. While this vaccine apparently offered protection against the Beta and Delta VOCs, further work is essential to assess the durability of immunity and the VE for the circulating VOCs.

* Important notice
medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
Ukraine Declares De Facto War on Hungary and Slovakia with Terror Drone Strikes on Their Gas Lifeline
A monster hit and a billion-dollar toy empire
Animated K-pop Musical ‘KPop Demon Hunters’ Becomes Netflix’s Most-Watched Original Animated Film
Canada: Nurse Suspended and Fined 93 Thousand Dollars After Stating the World’s Most Well-Known Fact Since the Creation of Adam and Eve, That There Are Only Two Genders
Elon Musk tweeted, “Europe is dying”
Far-Right Activist Convicted of Incitement Changes Gender and Demands: "Send Me to a Women’s Prison" | The Storm in Germany
Hungary Criticizes Ukraine: "Violating Our Sovereignty"
Will this be the first country to return to negative interest rates?
U.S. Treasury Secretary Whitney Bessent Backs Stablecoins to Boost Treasury Demand
Spain to Declare Disaster Zones After Massive Wildfires
Three-Minute Battery Swap Touted as Future of EVs
Beijing Military Parade to Showcase Weapons Advances
U.S. Tech Stocks Slide on AI Boom Concerns
White House Confirms Talks Over Intel Stake
Trump Suggests U.S. Could Support Ukraine ‘By Air’
Trump Called Viktor Orbán: "Why Are You Using the Veto"
Horror in the Skies: Plane Engine Exploded, Passengers Sent Farewell Messages
AI in Policing: Draft One Helps Speed Up Reports but Raises Legal and Ethical Concerns
Shame in Norway: Crown Princess’s Son Accused of Four Rapes
Apple Begins Simultaneous iPhone 17 Production in India and China
A Robot to Give Birth: The Chinese Announcement That Shakes the World
Finnish MP Dies by Suicide in Parliament Building
Outrage in the Tennis World After Jannik Sinner’s Withdrawal Storm
Class Action Lawsuit Against Volkswagen: Steering Wheel Switches Cause Accidents
UK Government Tries to Sue 4chan for Breaching Online Safety Act
Dogfights in the Skies: Airbus on Track to Overtake Boeing and Claim Aviation Supremacy
Tim Cook Promises an AI Revolution at Apple: "One of the Most Significant Technologies of Our Generation"
Are AI Data Centres the Infrastructure of the Future or the Next Crisis?
Miles Worth Billions: How Airlines Generate Huge Profits
Cambridge Dictionary Adds 'Skibidi,' 'Delulu,' and 'Tradwife' Amid Surge of Online Slang
Zelenskyy Returns to White House Flanked by European Allies as Trump Pressures Land-Swap Deal with Putin
The CEO Who Replaced 80% of Employees for the AI Revolution: "I Would Do It Again"
"Every Centimeter of Your Body Is a Masterpiece": The Shocking Meta Document Revealed
Character.ai Bets on Future of AI Companionship
China Ramps Up Tax Crackdown on Overseas Investments
Japanese Office Furniture Maker Expands into Bomb Shelter Market
Intel Shares Surge on Possible U.S. Government Investment
Hurricane Erin Threatens U.S. East Coast with Dangerous Surf
EU Blocks Trade Statement Over Digital Rule Dispute
EU Sends Record Aid as Spain Battles Wildfires
Beijing is moving into gold and other assets, diversifying away from the dollar
China Requires Data Centres to Source Majority of AI Chips Locally, For Technological Sovereignty
Escalating Clashes in Serbia as Anti-Government Protests Spread Nationwide
Category 5 Hurricane in the Caribbean: 'Catastrophic Storm' with Winds of 255 km/h
Trump Backs Putin’s Land-for-Peace Proposal Amid Kyiv’s Rejection
Digital Humans Move Beyond Sci-Fi: From Virtual DJs to AI Customer Agents
YouTube will start using AI to guess your age. If it’s wrong, you’ll have to prove it
Jellyfish Swarm Triggers Shutdown at Gravelines Nuclear Power Station in Northern France
OpenAI’s ‘PhD-Level’ ChatGPT 5 Stumbles, Struggles to Even Label a Map
Zelenskyy to Visit Washington after Trump–Putin Summit Yields No Agreement
×